Across TCGA pan-cancer cohorts, SHARPIN Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SHARPIN data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher SHARPIN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SHARPIN expression acts as an unfavorable survival marker.
SARC and LUAD are the cancer types where SHARPIN Mutation most reproducibly stratifies survival.